Tefibazumab Explained

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus.^[1]

It was developed by Inhibitex.^[2]

See also

• MSCRAMM (microbial surface components recognizing adhesive matrix molecules)

Notes and References

1. Pan A, Lorenzotti S, Zoncada A . Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection . Recent Patents on Anti-Infective Drug Discovery . 3 . 1 . 10–33 . January 2008 . 18221183 . 10.2174/157489108783413173 .
2. John JF . Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection . Current Opinion in Molecular Therapeutics . 8 . 5 . 455–60 . October 2006 . 17078388 .